Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 997-1003

  Zucman Rossi, Jessica ^a,b   Laurent Puig, Pierre ^b,c  

^a Université Paris 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

AKT; Axin1; Chromosome instability; CTNNB1; Gene mutation; HBV; Hepatocellular carcinoma; Targeted therapy; TP53; Transcriptome

Indexed keywords

AFLATOXIN B1; ANGIOGENESIS INHIBITOR; AZD 6244; BETA CATENIN; BEVACIZUMAB; CYTOSTATIC AGENT; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PLACEBO; PROTEIN KINASE B; SORAFENIB; UNCLASSIFIED DRUG; VINYL CHLORIDE; WNT PROTEIN;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER MORTALITY; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; DRUG POTENTIATION; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS B; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GENE TARGETING; HUMANS; LIVER NEOPLASMS; VARIATION (GENETICS);

HEPATITIS B VIRUS;

EID: 34548781396     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.997     Document Type: Review

References (46)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999).
2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase in primary liver cancer in the UK, 1979-1994. Lancet 350(9085), 1142-1143 (1997).
3. Edmondson HA, Peters RL: Tumors of the liver: pathologic features. Semin. Roentgenol. 18(2), 75-83 (1983).
4. Thorgeirsson S, Grisham J: Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31, 332-336 (2002).
5. Donato F, Gelatti U, Limina RM, Fattovich G: Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 25(27), 3756-3770 (2006).
6. Seeff LB, Hoofnagle JH: Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 25(27), 3771-3777 (2006).
7. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004).
8. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C: Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25(27), 3823-3833 (2006).
9. Aoki H, Kajino K, Arakawa Y, Hino O: Molecular cloning of a rat chromosome putative recombinogenic sequence homologous to the hepatitis B virus encapsidation signal. Proc. Natl Acad. Sci. U.S.A. 93(14), 7300-7304 (1996).
10. Ferber MJ, Montoya DP, Yu C et al.: Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22(24), 3813-3820 (2003).
11. Murakami S: Hepatitis B virus X protein: structure, function and biology. Intervirology 42(2-3), 81-99 (1999).
12. Paterlini-Brechot P, Saigo K, Murakami Y et al.: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22(25), 3911-3916 (2003).
13. Feitelson MA, Zhu M, Duan LX, London WT: Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8(5), 1109-1117 (1993).
14. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350(6317), 429-431 (1991).
15. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A: Frequent κ- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br. J. Cancer 84(7), 982-989 (2001).
16. Bluteau O, Jeannot E, Bioulac-Sage P et al.: Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 32(2), 312-315 (2002).
17. Yakicier Y, Legoix P, Vaury C et al.: Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20(37), 5232-5238 (2001).
18. Bluteau O, Beaudoin J-C, Pasturaud P et al.: Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 21, 1225-1232 (2002).
19. Laurent-Puig P, Legoix P, Bluteau O et al.: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120(7), 1763-1773 (2001).
20. Laurent-Puig P, Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene 25(27), 3778-3786 (2006).
21. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC: TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26(15), 2166-2176 (2007).
22. La Coste A, Romagnolo B, Billuart P et al.: Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA 95(15), 8847-8851 (1998).
23. Miyoshi Y, Iwao K, Nagasawa Y et al.: Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58(12), 2524-2527 (1998).
24. Satoh S, Daigo Y, Furukawa Y et al.: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24(3), 245-250 (2000).
25. Legoix P, Bluteau O, Bayer J et al.: β-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 18(27), 4044-4046 (1999).
26. Zucman-Rossi J, Benhamouche S, Godard C et al.: Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas. Oncogene 26(5), 774-780 (2007).
27. Liew CT, Li HM, Lo KW et al.: High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18(3), 789-795 (1999).
28. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H: p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116(2), 394-400 (1999).
29. Lin Y, Shi CY, Li B et al.: Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Ann. Acad. Med. Singapore 25(1), 22-30 (1996).
30. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL: M6P/ IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat. Genet. 11(4), 447-449 (1995).
31. Hu TH, Huang CC, Lin PR et al.: Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97(8), 1929-1940 (2003).
32. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL: Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res. 37(5), 389-396 (2007).
33. Yao YJ, Ping XL, Zhang H et al.: PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 18(20), 3181-3185 (1999).
34. Boyault S, Rickman DS, de Reynies A et al.: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1), 42-52 (2007).
35. Roberts LR, Gores GJ: Emerging drugs for hepatocellular carcinoma. 11(3), 469-487 (2006).
36. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092), 424-430 (2006).
37. Liu L, Cao Y, Chen C et al.: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
38. Abou-Alfa GK, Schwartz L, Ricci S et al.: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006).
39. Llovet J, Ricci S, Mazzaferro V et al.: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol. 25(18S), LBA1 (2007).
40. Huynh H, Soo KC, Chow PK, Tran E: Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol. Cancer Ther. 6(1), 138-146 (2007).
41. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H: Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J. Hepatol. 43(4), 661-669 (2005).
42. Philip PA, Mahoney MR, Allmer C et al.: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23(27), 6657-6663 (2005).
43. Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C: A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 6, 278 (2006).
44. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28(1), 68-77 (1998).
45. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
46. Zhu AX, Blaszkowsky LS, Ryan DP et al.: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(12), 1898-1903 (2006).